Why the study?
Does abciximab and unfractionated heparin reduce the primary end point compared to bivalirudin in patients with non-ST-segment elevation myocardial infarction undergoing PCI?
Does abciximab and unfractionated heparin reduce the primary end point compared to bivalirudin in patients with non-ST-segment elevation myocardial infarction undergoing PCI?
In patients with NSTEMI undergoing PCI, the combination of abciximab and unfractionated heparin does not improve primary outcomes and increases bleeding risk compared to bivalirudin.
Bivalirudin preferred over abciximab plus heparin in NSTEMI PCI; challenges routine glycoprotein IIb/IIIa inhibitor use.
Abciximab and unfractionated heparin, as compared with bivalirudin, failed to reduce the rate of the primary end point and increased the risk of bleeding among patients with non-ST-segment elevation myocardial infarction who were undergoing PCI. (Funded by Nycomed Pharma and others; ISAR-REACT 4 ClinicalTrials.gov number, NCT00373451.).
No takes yet. Share an insight, caveat, or question.
Kastrati et al. (2011) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: